Hanall Biopharma Yönetim

Sean Jeong, also known as Seungwon, M.D., MBA, serves as President & Director at Hanall Biopharma Co.,Ltd since 2021 and is its Co-Chief Executive Officer since April 2023 and was its Chief Executive Offic...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sean Jeong	President	1.6yrs	Veri yok	Veri yok
Su-Jin Park	Co-CEO, VP & Director	1.6yrs	Veri yok	0.0037% ₩ 67.0m
Christopher Slavinsky	Chief Business Development & Legal Officer	less than a year	Veri yok	Veri yok
Nam-Yong Cho	Senior Executive Director of Sales & Marketing and Senior Managing Director	no data	Veri yok	Veri yok

1.6yrs

Ortalama Görev Süresi

Deneyimli Yönetim: A009420 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.6 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sean Jeong	President	3.8yrs	Veri yok	Veri yok
Su-Jin Park	Co-CEO, VP & Director	1.6yrs	Veri yok	0.0037% ₩ 67.0m
Sung-Hou Kim	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Seung-Kook Park	Director	no data	Veri yok	0.16% ₩ 3.0b
Jae-Ho Cheong	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Yong Choi	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Aekyung Kim	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Young Shin	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jason Song	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jae-chun Yoon	Chairman	no data	Veri yok	Veri yok
Hun Jung	Independent Director	3.8yrs	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: A009420 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

Hanall Biopharma Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Hanall Biopharma Co., Ltd. Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer

Hanall Biopharma Co., Ltd. Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer

Hanall Biopharma Co., Ltd., Annual General Meeting, Mar 28, 2024

Less than half of directors are independent

Less than half of directors are independent

Hanall Biopharma Co.,Ltd, Annual General Meeting, Mar 26, 2021

Recent updates

Hanall Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of A First-In-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease

Now 23% undervalued

Hanall Biopharma Co., Ltd.'s (KRX:009420) 30% Share Price Surge Not Quite Adding Up

Consensus EPS estimates increase by 23%, revenue downgraded

Now 22% undervalued after recent price drop

Hanall Biopharma Co., Ltd. Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer

Hanall Biopharma Co., Ltd. Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Hanall Biopharma Co., Ltd. (KRX:009420)

Consensus EPS estimates fall by 45%, revenue upgraded

Getting In Cheap On Hanall Biopharma Co., Ltd. (KRX:009420) Is Unlikely

Consensus EPS estimates fall by 12%

There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings

Hanall Biopharma Co., Ltd., Annual General Meeting, Mar 28, 2024

Full year 2023 earnings released: EPS: ₩69.00 (vs ₩5.00 in FY 2022)

Price target increased by 11% to ₩44,667

Price target increased by 8.5% to ₩42,333

Consensus EPS estimates increase by 16%

New major risk - Share price stability

Price target increased by 14% to ₩35,800

Now 20% undervalued

Full year 2022 earnings released: EPS: ₩5.00 (vs ₩174 in FY 2021)

Less than half of directors are independent

Hanall's Second FcRn Inhibitor HL161ANS to Be Added to the Development Program of Its Licensed Partner

Price target decreased to ₩29,000

Less than half of directors are independent

Price target decreased to ₩45,500

First quarter 2021 earnings released: EPS ₩88.00 (vs ₩76.00 in 1Q 2020)

Hanall Biopharma Co.,Ltd, Annual General Meeting, Mar 26, 2021

Full year 2020 earnings released: EPS ₩386 (vs ₩375 in FY 2019)

New 90-day low: ₩23,400

Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years

Investor sentiment deteriorated over the past week

New 90-day low: ₩32,050

What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?

Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

New 90-day high: ₩39,000

Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?

Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching

Market bids up stock over the past week

New 90-day low: ₩27,600

Price target raised to ₩41,500

New 90-day high - ₩34,600

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi